|
BioAnaLab is a company that was spun out of the Theraputic Antibody Centre at the University of Oxford. It offers a contract testing service for Biopharmaceuticals, particularly in the in the rapidly growing area of monoclonal antibodies, which are the basis of perhaps 30% of all drugs in clinical trials.
BioAnaLab was set up to provide services based on the experience of its founders at the University of Oxford where they had developed a large number of therapeutic monoclonal antibodies, including CAMPATH®.
Since our initial investment the company has made significant progress under its CEO and founder Geoff Hale. In 2005 the company closed a new round of institutional investment led by Octopus Fund Managers, which has helped to further develop the company and its offerings to the market. In addition the company has appointed David Oxlade to the board as Chairman. David is a strong addition to the company being a leading light in the UK Pharmaceutical industry. |
